A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
← catalyst calendarNCT06226571 · readout ≤ 193 d
Sponsored by Syndax Pharmaceuticals (industry) · SNDX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
76actual
Sites
48
Countries
Australia, Canada, Netherlands +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-21 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemias
Interventions
- Drug: SNDX-5613
- Drug: Chemotherapy Regimen
- Drug: HiDAC
Primary outcomes
what the primary-completion date above is the date OFDose Escalation: Number of Participants with Dose-limiting Toxicities
measured Up to Day 42
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
measured Day 1 through 30 days after final dose (up to approximately 3 years)
Permalink · SNDX's whole pipeline · Catalyst calendar · Every registered study · What changed